ReviewCurrent microbiology2025
Harnessing the Potential of IgY: A Creative Approach for Immunodiagnosis and Immunotherapy Against Viral Diseases of Animals.
Review in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies, apart from their irreplaceable role in immune defense, have been exploited as a successful diagnostic and therapeutic tool for many years. A major milestone was achieved in the late-twentieth century with the development of IgY technology, which introduced avian antibodies as an alternative to conventional mammalian antibodies. The distinctive structural features of IgY, coupled with ease of large-scale production, account for many advantages over mammalian IgG. Over the years, the diagnostic and therapeutic potential of IgY has been investigated across diverse applications in livestock, poultry, livestock, companion animals and humans, producing promising outcomes against a wide range of infectious diseases. Several IgY-based products are already available commercially, while many others remain under experimental development. Despite these advances, monoclonal IgY technology is still emerging and has not yet reached broad clinical application. The present review provides comprehensive insights into the production and applications of IgY antibodies, with particular emphasis on their role in combating viral diseases in animals.
Indexed as
Identifiers
41044353What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.